AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28235522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination prior to spinal anesthetic placement
Number of subjects: 80
Study 28235522 — intervention group
Group type: COMPARATOR
Intervention: Landmark technique only
Number of subjects: 80
Study 25341548 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% topical sildenafil cream applied to left extremities
Number of subjects: 10
Study 25341548 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% topical sildenafil cream applied to right extremities
Number of subjects: 10
Study 25341548 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% topical sildenafil cream
Number of subjects: 10
Study 25341548 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied to opposite extremity
Number of subjects: 10
Study 24347531 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable pump
Number of subjects: 20
Study 24347531 — intervention group
Group type: COMPARATOR
Intervention: Pole-mounted pump
Number of subjects: 20
Study 21905270 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (Nutropin AQ)
Number of subjects: 68
Study 21905270 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study 19064988 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant letrozole
Number of subjects: 114
Study 19064988 — intervention group
Group type: COMPARATOR
Intervention: letrozole plus metronomic cyclophosphamide
Number of subjects: 114
Study 17446014 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Recovery Group (WRG)
Number of subjects: 0
Study 17446014 — intervention group
Group type: COMPARATOR
Intervention: Mixed-gender Group Drug Counseling (GDC)
Number of subjects: 0
Study 15595934 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/DDCI/entacapone
Number of subjects: 270
Study 15595934 — intervention group
Group type: COMPARATOR
Intervention: levodopa/DDCI/placebo
Number of subjects: 270
Study 12123209 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 161
Study 12123209 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 161
Study 10192709 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 2 g/day and Ethambutol 20 mg/kg/day
Number of subjects: 34
Study 10192709 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 2 g/day, Ethambutol 20 mg/kg/day, and Clofazimine 200 mg/day
Number of subjects: 34
Study 7778534 — intervention group
Group type: EXPERIMENTAL
Intervention: Delapril (7.5 mg twice daily, can be doubled to 30 mg twice daily)
Number of subjects: 0
Study 7778534 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (2.5 mg twice daily, can be doubled to 10 mg twice daily)
Number of subjects: 0
Study 2271852 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (20 patients)
Number of subjects: 40
Study 2271852 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (20 patients)
Number of subjects: 40
Study 6985791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin sodium
Number of subjects: 400
Study 6985791 — intervention group
Group type: COMPARATOR
Intervention: Oxacillin sodium
Number of subjects: 400
Study 28910673 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness curriculum with parental involvement (N=191)
Number of subjects: 555
Study 28910673 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness curriculum without parental involvement (N=186)
Number of subjects: 555
Study 28910673 — intervention group
Group type: COMPARATOR
Intervention: Usual curriculum control group (N=178)
Number of subjects: 555
Study 26160763 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 270
Study 26160763 — intervention group
Group type: COMPARATOR
Intervention: Control (without TachoSil)
Number of subjects: 270
Study 26160763 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn closure
Number of subjects: 270
Study 26160763 — intervention group
Group type: COMPARATOR
Intervention: Mechanical closure
Number of subjects: 270
Study 26160763 — intervention group
Group type: COMPARATOR
Intervention: Splenic vessel ligation
Number of subjects: 270
Study 26160763 — intervention group
Group type: COMPARATOR
Intervention: Vascular preservation
Number of subjects: 270
Study 23246646 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g lactose
Number of subjects: 120
Study 23246646 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g lactose
Number of subjects: 120
Study 23246646 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g lactose
Number of subjects: 120
Study 23246646 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported lactose intolerance (LI)
Number of subjects: 120
Study 23246646 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy product intake
Number of subjects: 120
Study 23246646 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen breath tests
Number of subjects: 120
Study 21990298 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/d of all rac-α-tocopheryl acetate)
Number of subjects: 35533
Study 21990298 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 μg/d from L-selenomethionine)
Number of subjects: 35533
Study 21990298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both selenium and vitamin E
Number of subjects: 35533
Study 21990298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35533
Study 19858965 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial affect recognition (FAR)
Number of subjects: 19
Study 19858965 — intervention group
Group type: EXPERIMENTAL
Intervention: Stories of emotional inference (SEI)
Number of subjects: 19
Study 17319827 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher platelet dose (HDP)
Number of subjects: 5
Study 17319827 — intervention group
Group type: COMPARATOR
Intervention: Lower platelet dose (LDP)
Number of subjects: 5
Study 15067363 — intervention group
Group type: EXPERIMENTAL
Intervention: Germinated barley foodstuff (GBF) 20 g daily
Number of subjects: 59
Study 15067363 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 59
Study 15067363 — intervention group
Group type: EXPERIMENTAL
Intervention: Germinated barley foodstuff (GBF) with steroid tapering treatment
Number of subjects: 59
Study 12127385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil treatment
Number of subjects: 27
Study 12127385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil) treatment
Number of subjects: 27
Study 9876955 — intervention group
Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 0
Study 9876955 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline and Vitamin E
Number of subjects: 0
Study 7981584 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to nucleoli in acute EMS patients
Number of subjects: 167
Study 7981584 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to nucleoli in chronic EMS patients
Number of subjects: 167
Study 7981584 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to nucleoli in FS patients
Number of subjects: 167
Study 7981584 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to 5-HT in FS patients
Number of subjects: 167
Study 7981584 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to 5-HT in acute EMS patients
Number of subjects: 167
Study 7981584 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to 5-HT in EMS patients after 2 years
Number of subjects: 167
Study 7981584 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to Gm1 in acute EMS patients
Number of subjects: 167
Study 7981584 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to Gm1 in chronic EMS patients
Number of subjects: 167
Study 7981584 — intervention group
Group type: COMPARATOR
Intervention: Antibodies in healthy controls
Number of subjects: 167
Study 2547312 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucomannan (1 g tid orally)
Number of subjects: 31
Study 2547312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 616216 — intervention group
Group type: EXPERIMENTAL
Intervention: Finnish sauna bath without beta-blockade
Number of subjects: 5
Study 616216 — intervention group
Group type: COMPARATOR
Intervention: Finnish sauna bath with beta-blockade (Oxprenolol 40 mg)
Number of subjects: 5
Study 616216 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to cool swimming pool (22 degrees C) after sauna
Number of subjects: 5
Study 616216 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest period of 15 min after cool pool
Number of subjects: 5
Study 31913252 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) 70 ml
Number of subjects: 11
Study 31913252 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL; black currant juice)
Number of subjects: 11
Study 31122975 — intervention group
Group type: COMPARATOR
Intervention: High-intensity interval training (HIIT) sessions facilitated by teachers, at least two sessions per week during lesson-time for 3 months, followed by encouragement for sessions outside lesson-time for an additional 6 months.
Number of subjects: 720
Study 31122975 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention during the study period).
Number of subjects: 720
Study 29151559 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about action plans according to self-monitoring program
Number of subjects: 66
Study 26518207 — intervention group
Group type: EXPERIMENTAL
Intervention: IBWL + ES (internet program plus extra support)
Number of subjects: 100
Study 26518207 — intervention group
Group type: COMPARATOR
Intervention: IBWL early non-responders
Number of subjects: 100
Study 26518207 — intervention group
Group type: COMPARATOR
Intervention: Early responders (both treatment arms)
Number of subjects: 100
Study 22744410 — intervention group
Group type: EXPERIMENTAL
Intervention: PerFix™ plug
Number of subjects: 95
Study 22744410 — intervention group
Group type: COMPARATOR
Intervention: 4DDOME(®) implant
Number of subjects: 95
Study 20507399 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-n-butylresorcinol 0.1% cream
Number of subjects: 23
Study 20507399 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 23
Study 18779478 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac tromethamine, 0.4%
Number of subjects: 109
Study 18779478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 15877875 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleurone flour (ALF) - 175 g bread made with ALF and placebo tablet each day
Number of subjects: 75
Study 15877875 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (FA) - 175 g bread made with PCS flour and tablet containing 640 microg folic acid each day
Number of subjects: 75
Study 15877875 — intervention group
Group type: COMPARATOR
Intervention: Pericarp seed coat (PCS) - 175 g bread made with PCS flour and placebo tablet each day
Number of subjects: 75
Study 12931365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50-100 mg)
Number of subjects: 0
Study 12931365 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (40 mg)
Number of subjects: 0
Study 12931365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10710012 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (3.5 mg/kg)
Number of subjects: 21
Study 10710012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11322246 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of saquinavir plus 200 mg of zidovudine
Number of subjects: 92
Study 11322246 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of saquinavir plus 200 mg of zidovudine
Number of subjects: 92
Study 11322246 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine monotherapy
Number of subjects: 92
Study 11322246 — intervention group
Group type: COMPARATOR
Intervention: Other combination therapies (75 mg, 200 mg saquinavir with zidovudine)
Number of subjects: 92
Study 1934045 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccine
Number of subjects: 61
Study 1934045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 6138058 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 20
Study 6138058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 20
Study 6138058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31969687 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led physical activity intervention
Number of subjects: 300
Study 31969687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention training for physiotherapists
Number of subjects: 300
Study 31766977 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed Ticagrelor (CTIC) 180 mg
Number of subjects: 100
Study 31766977 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide bolus (180 μg/kg×2 intravenous boluses) plus Clopidogrel (600 mg)
Number of subjects: 100
Study 31766977 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide bolus plus Clopidogrel
Number of subjects: 100
Study 31766977 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed Ticagrelor (CTIC)
Number of subjects: 100
Study 31766977 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 28615145 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (n=58)
Number of subjects: 118
Study 28615145 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (n=60)
Number of subjects: 118
Study 25697454 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week balance training program with external focus instructions
Number of subjects: 49
Study 25697454 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week balance training program with internal focus instructions
Number of subjects: 49
Study 25697454 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week balance training program with no focus instructions
Number of subjects: 49
Study 25697454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no balance training)
Number of subjects: 49
Study 24016553 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing and telephone contact (Intervention Group)
Number of subjects: 1598
Study 24016553 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control Group)
Number of subjects: 1598
Study 22402329 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg for four days
Number of subjects: 270
Study 22402329 — intervention group
Group type: COMPARATOR
Intervention: Control (uneventful recovery)
Number of subjects: 270
Study 22402329 — intervention group
Group type: COMPARATOR
Intervention: Control (adverse outcome)
Number of subjects: 270
Study 22402329 — intervention group
Group type: COMPARATOR
Intervention: Overall population (270 patients)
Number of subjects: 270
Study 19680473 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rizatriptan
Number of subjects: 10
Study 19680473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17237316 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified dairy product containing eicosapentaenoic acid, docosahexaenoic acid, oleic acid, folic acid, and vitamins A, B‐6, D, and E (500 mL/d)
Number of subjects: 40
Study 17237316 — intervention group
Group type: COMPARATOR
Intervention: Semi‐skimmed milk with added vitamins A and D (500 mL/d)
Number of subjects: 40
Study 16784831 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron hydrochloride 1mg rapidly disintegrating tablets
Number of subjects: 0
Study 16784831 — intervention group
Group type: COMPARATOR
Intervention: Granisetron hydrochloride 1mg capsules
Number of subjects: 0
Study 15240527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CEE 0.625 mg/day
Number of subjects: 226
Study 15240527 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal E2 50 microg/day
Number of subjects: 226
Study 15240527 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide 100 mg/twice a day
Number of subjects: 226
Study 15240527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 15240527 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (both CEE and E2)
Number of subjects: 226
Study 11074185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB) as add-on therapy
Number of subjects: 277
Study 11074185 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT) as add-on therapy
Number of subjects: 277
Study 11074185 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) as add-on therapy
Number of subjects: 277
Study 8990684 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Composite Sealant Restoration (MCR)
Number of subjects: 58
Study 8990684 — intervention group
Group type: COMPARATOR
Intervention: Glass Ionomer Sealant Restoration (GSR)
Number of subjects: 58
Study 1424620 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (ethinyl estradiol and gestodene)
Number of subjects: 1933
Study 3883735 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 12
Study 31005588 — intervention group
Group type: EXPERIMENTAL
Intervention: VR mApp
Number of subjects: 105
Study 31005588 — intervention group
Group type: COMPARATOR
Intervention: mApp
Number of subjects: 105
Study 28165546 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard management (SM) associated with oral daily supplementation of 120 mg cranberry extract (Anthocran®), standardized to 36 mg proanthocyanidins for 60 days
Number of subjects: 36
Study 28165546 — intervention group
Group type: COMPARATOR
Intervention: Standard management (SM)
Number of subjects: 36
Study 28165546 — intervention group
Group type: EXPERIMENTAL
Intervention: Before inclusion (baseline)
Number of subjects: 36
Study 25584474 — intervention group
Group type: EXPERIMENTAL
Intervention: Active observation with checklist
Number of subjects: 232
Study 25584474 — intervention group
Group type: COMPARATOR
Intervention: Passive observation
Number of subjects: 232
Study 23695976 — intervention group
Group type: EXPERIMENTAL
Intervention: BrAC estimation training
Number of subjects: 46
Study 23695976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 46
Study 20530107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-delivered mask ventilation (VDMV)
Number of subjects: 36
Study 20530107 — intervention group
Group type: COMPARATOR
Intervention: Laerdal self-inflating bag (SIB)
Number of subjects: 36
Study 20530107 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetic bag and T-piece Neopuff
Number of subjects: 36
Study 19517672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous piracetam 30 mg kg(‐1)
Number of subjects: 250
Study 19517672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 17090953 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4) administration after 2 months of therapy
Number of subjects: 24
Study 17090953 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4) administration
Number of subjects: 24
Study 17090953 — intervention group
Group type: COMPARATOR
Intervention: No L-thyroxine (L-T4) treatment
Number of subjects: 24
Study 15310558 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoamine oxidase type B inhibitors (MAOBIs)
Number of subjects: 3525
Study 15310558 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 3525
Study 11783838 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard discectomy for proven disc herniation (<= 1 year)
Number of subjects: 0
Study 11783838 — intervention group
Group type: EXPERIMENTAL
Intervention: Local triamcinolone injection for lateral epicondylitis (<= 12 weeks)
Number of subjects: 0
Study 11783838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative steroid at discectomy
Number of subjects: 0
Study 11783838 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injection for sciatica with low back pain
Number of subjects: 0
Study 11783838 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal steroid injection for low back pain
Number of subjects: 0
Study 11783838 — intervention group
Group type: EXPERIMENTAL
Intervention: Local glycosaminoglycan polyphosphate injection for lateral epicondylitis
Number of subjects: 0
Study 11783838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular steroid injection for shoulder arthritis
Number of subjects: 0
Study 11783838 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial steroid injections for rotator cuff tendinitis
Number of subjects: 0
Study 11783838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific injections for painful shoulder
Number of subjects: 0
Study 11783838 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic growth hormone for fibromyalgia
Number of subjects: 0
Study 11783838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenosine for fibromyalgia
Number of subjects: 0
Study 11783838 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injections with steroid and local anesthetic
Number of subjects: 0
Study 9395805 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAb positivity in Graves' disease (GD) patients
Number of subjects: 265
Study 9395805 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAb positivity in chronic lymphocytic thyroiditis (CLT) patients
Number of subjects: 265
Study 9395805 — intervention group
Group type: COMPARATOR
Intervention: TRAb positivity in other thyroid disorders
Number of subjects: 265
Study 9395805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity of TRAb compared to anti-thyroglobulin antibodies
Number of subjects: 265
Study 9395805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity of TRAb compared to anti-microsomal antibodies
Number of subjects: 265
Study 9395805 — intervention group
Group type: EXPERIMENTAL
Intervention: Specificity of TRAb levels > 10.0 U/L
Number of subjects: 265
Study 7957520 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal dexmedetomidine (625 micrograms applied for 12 h)
Number of subjects: 9
Study 7957520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (2.0 micrograms.kg‐1 as dexmedetomidine hydrochloride administered as an infusion over 5 min)
Number of subjects: 9
Study 7957520 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal dexmedetomidine
Number of subjects: 9